Technology

New Webinar: The Hunt for NASH Therapies, 11 July 2019

NASH is present in nine to 18 million people in America alone. Yet no single drug has yet been approved for its treatment. To discuss why therapies are proving so elusive, and where efforts will be made in the future, FLG has gathered some of the most influential names in the field to discuss the problem in our latest webinar: New Approaches to the Old Hunt for NASH Therapies, held at 4pm on 11 July 2019.

Inscripta’s CREATE Technology Set to Expand CRISPR’s Potential

Inscripta has presented its scalable platform for benchtop digital CRISPR engineering, described as world first, at the 2019 Synthetic Biology: Engineering, Evolution & Design (SEED) conference. The technology, “CRISPR-enabled trackable genome engineering” or CREATE, is meant to remove certain limitations of CRISPR to allow for more wide-reaching research in the future.

Abbvie Acquires Allergan for $63 Billion

Biopharma giant Abbvie has announced the acquisition of Allergan for $63 billion in cash and stock. Abbvie said the deal would be “transformational” for both companies, allowing Abbvie to diversify its business while focusing on scientific research and the company’s pipeline.

Real-World Solutions to your Drug Development Problems

The amount of data captured by pharma companies today is fast outpacing best use for it. The ever-evolving scope of the field also means that many senior-level professionals do not fully understand the importance of getting data right in their business, or missing a potential opportunity that their rivals seize. Stemming from Front Line Genomics’ […]

Illumina’s $1.2 Billion PacBio Takeover Threatened by CMA Concerns

The CMA has announced that Illumina’s $1.2 billion acquisition of Pac Bio is potentially anti-competitive, delaying the expected conclusion of the deal until fourth quarter 2019. The CMA said the deal could remove Illumina’s biggest competitor, leaving limited alternatives available for customers.

Russian Scientist Plans to CRISPR-Edit More Babies

Russian biologist Denis Rebrikov has announced his intentions to produce further gene-edited babies, ignoring the scientific consensus that this should not be done until an ethical framework is constructed to regulate the science involved. Rebrikov’s plans could occur before the end of the year if he receives approval in time.

New “Jumping Gene” CRISPR Directly Inserts DNA

A new experimental version of CRISPR could help fix genes rather than disable them using transposons, or “jumping genes”. This could help move the current “find and delete” purpose of CRISPR to the more useful “find and replace” one.

Stem Cells Edited In Vivo For the First Time

Researchers have genetically modified stem cells inside the bodies of mice for the first time, in a study that could lead eventually to new potential for stem cell therapies. The study also shows potential for studying genetically-edited stem cells within the body, rather than in the lab.

CRISPR Twins’ Lives Could Be Shortened by Two Years

He Jiankui, the Chinese scientist who created the first gene-edited twin children last year, could have unknowingly shortened their lives by more than 1.9 years. A study into the DNA and death records of 400,000 volunteers in the UK Biobank found the genetic mutations to gene CCR5 were “of quite strong effect.”

Fungus Genetically Modified to Wipe Out Malaria-Carrying Mosquitoes

University of Maryland scientists have genetically modified a fungus to produce a toxin fatal to mosquitoes, in order to reduce the malaria death toll they currently cause. An out-of-lab trial destroyed a mosquito population almost entirely within 45 days, leading some to criticise the work as “too dangerous” for the real world.